{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:16:19Z","timestamp":1793160979790,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ygyno.2017.06.013","type":"journal-article","created":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T17:01:22Z","timestamp":1497632482000},"page":"427-435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Management of menopausal symptoms in women with gynecologic cancers"],"prefix":"10.1016","volume":"146","author":[{"given":"Marcela G.","family":"del Carmen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel W.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2017.06.013_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0010","doi-asserted-by":"crossref","first-page":"447e","DOI":"10.1016\/j.ygyno.2011.03.012","article-title":"Hormone replacement therapy in gynecologic cancer survivors: why not?","volume":"122","author":"Ibeanu","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/GME.0000000000000319","article-title":"The North American Menopause Society recommendations for clinical care of midlife women","volume":"21","author":"Shifren","year":"2014","journal-title":"Menopause"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1258\/mi.2010.010018","article-title":"Menopause, hormone replacement and gynaecological cancers","volume":"16","author":"Hinds","year":"2010","journal-title":"Menopause Int."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0025","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Writing group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0030","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women","volume":"280","author":"Hulley","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jama.288.1.49","article-title":"Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen\/Progestin Replacement Study follow-up (HERS II)","volume":"288","author":"Grady","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0040","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled Trial","volume":"291","author":"The Women's Health Initiative Steering Committee","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0045","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0050","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/AOG.0000000000001058","article-title":"Management of menopausal symptoms","volume":"126","author":"Kaunitz","year":"2015","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0020-7292(96)02719-1","article-title":"Diagnosis and management of malignant germ cell ovarian tumors in young females","volume":"55","author":"Zalel","year":"1996","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0060","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.ygyno.2005.02.022","article-title":"Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer","volume":"97","author":"GotliebWH","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0065","first-page":"157","article-title":"Androgens and ovarian cancers","volume":"25","author":"Wang","year":"2004","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0070","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<1013::AID-CNCR17>3.0.CO;2-1","article-title":"Estrogen replacement therapy for ovarian carcinoma survivors: a randomised control trial","volume":"86","author":"Guidozzi","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0075","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1002\/ijc.22218","article-title":"Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival","volume":"119","author":"Mascarenhas","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0080","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.2015.60.9719","article-title":"Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial","volume":"33","author":"Eeles","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0085","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/GME.0000000000000508","article-title":"Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis","volume":"23","author":"Pergialiotis","year":"2016","journal-title":"Menopause"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0090","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.maturitas.2009.11.017","article-title":"Hormone replacement after gynaecological cancer","volume":"65","author":"Singh","year":"2010","journal-title":"Maturitas"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0095","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/jnci\/91.13.1131","article-title":"Risk of endometrial cancer following estrogen replacement therapy with and without progestin","volume":"91","author":"Weiderpass","year":"1991","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0100","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2005.02.8464","article-title":"Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynaecologic Oncology Group study","volume":"24","author":"Barakat","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0105","first-page":"326","article-title":"Estrogen replacement therapy in the patient treated for endometrial cancer","volume":"67","author":"Creasman","year":"1986","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0110","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0090-8258(90)90171-G","article-title":"Estrogen replacement therapy following treatment for stage 1 endometrial carcinoma","volume":"36","author":"Lee","year":"1990","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0115","first-page":"555","article-title":"Estrogen replacement therapy in endometrial cancer patients: a matched control study","volume":"97","author":"Suriano","year":"2001","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0120","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0002-9378(96)70027-3","article-title":"Estrogen replacement in surgical stage I and II endometrial cancer survivors","volume":"175","author":"Chapman","year":"1996","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0125","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1525-1438.2006.00526.x","article-title":"Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors?","volume":"16","author":"Ayhan","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0130","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1097\/IGC.0000000000000290","article-title":"Uterine leiomyosarcoma: a review article","volume":"24","author":"Gockley","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0135","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/IGC.0000000000000372","article-title":"Trends in the treatment of uterine leiomyosarcoma in the Medicare population","volume":"25","author":"Foley","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0140","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ygyno.2005.11.010","article-title":"Harm or benefit of hormone replacement in metastatic low-grade endometrial stromal sarcoma: single centre experience with 10 cases and review of literature","volume":"101","author":"Pink","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0145","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00129039-200412000-00008","article-title":"Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study","volume":"12","author":"Kelley","year":"2004","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0150","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/cncr.23245","article-title":"Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy","volume":"112","author":"Kapp","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0155","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0090-8258(87)90170-3","article-title":"Incidence of ovarian metastasis in patients with cancer of uterine cervix","volume":"28","author":"Tabata","year":"1987","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0160","first-page":"1341","article-title":"Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters","volume":"30","author":"Bodner","year":"2010","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0165","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0090-8258(87)90270-8","article-title":"Hormonal replacement therapy in patients after cervical cancer treatment","volume":"26","author":"Ploch","year":"1987","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0170","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0090-8258(86)90134-4","article-title":"The influence of estrogen and progesterone receptors on survival in patients with carcinoma of the uterine cervix","volume":"23","author":"Martin","year":"1986","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0175","first-page":"237","article-title":"Changes in the uterus after eradication of endometrial adenocarcinoma by radiotherapy","volume":"39","author":"Sheehan","year":"1943","journal-title":"Arch. Pathol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0180","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0029-7844(95)00101-V","article-title":"Carcinoma of vulva in young women","volume":"86","author":"Messing","year":"1995","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0185","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1002\/ijc.23446","article-title":"Risk factors for invasive squamous cell carcinoma of the vulva and vagina\u2014population-based case\u2013control study in Denmark","volume":"122","author":"Madsen","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0190","first-page":"857","article-title":"Hormonal factors in vulvar cancer. A case\u2013control study","volume":"39","author":"Sherman","year":"1994","journal-title":"J. Reprod. Med."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0195","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/(SICI)1097-0142(19980901)83:5<1033::AID-CNCR30>3.0.CO;2-6","article-title":"The National Cancer Data Base report on cancer of the vagina","volume":"83","author":"Creasman","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0200","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJM198702263160905","article-title":"Rates and risks of diethylstilbestrolrelated clear-cell adenocarcinoma of the vagina and cervix. An update","volume":"316","author":"Melnick","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0205","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1054\/bjoc.2000.1521","article-title":"Long-term cancer risk in women given diethylstilbestrol (DES) during pregnancy","volume":"84","author":"Titus-Ernstoff","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0210","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(08)60346-3","article-title":"Menopause","volume":"371","author":"Nelson","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0215","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/GME.0000000000000196","article-title":"Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort","volume":"21","author":"Freeman","year":"2014","journal-title":"Menopause"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0220","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/01.AOG.0000441353.20693.78","volume":"123","year":"2014","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0225","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/GME.0b013e3182a66aa7","article-title":"Low-dose paroxetine 7.5mg for menopausal vasomotor symptoms: two randomized controlled trials","volume":"20","author":"Simon","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0230","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1001\/jamainternmed.2014.1891","article-title":"Low-dose estradiol and the serotoninnorepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial","volume":"174","author":"Joffe","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0235","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.6004\/jnccn.2010.0086","article-title":"Nonhormonal management of hot flashes for women on risk reduction therapy","volume":"8","author":"Sideras","year":"2010","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"4","key":"10.1016\/j.ygyno.2017.06.013_bb0240","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/ajhb.1077","article-title":"Physiology of hot flashes","volume":"13","author":"Freedman","year":"2001","journal-title":"Am. J. Hum. Biol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0245","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/gme.0b013e31826ce3ed","article-title":"Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial","volume":"20","author":"Elkins","year":"2013","journal-title":"Menopause"},{"issue":"Issue 7","key":"10.1016\/j.ygyno.2017.06.013_bb0250","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007410.pub2","article-title":"Acupuncture for menopausal hot flushes.","author":"Dodin","year":"2013","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0255","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/GME.0b013e31829e4089","article-title":"Efficacy of exercise for menopausal symptoms: a randomized controlled trial","volume":"21","author":"Sternfeld","year":"2014","journal-title":"Menopause"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0260","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11606-012-2202-6","article-title":"Paced respiration for vasomotor and other menopausal symptoms: a randomized, controlled trial","volume":"28","author":"Carpenter","year":"2013","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0265","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2147\/IJWH.S53652","article-title":"Effectiveness of a modified version of the applied relaxation technique in treatment of perimenopausal and postmenopausal symptoms","volume":"5","author":"Saensak","year":"2013","journal-title":"Int. J. Womens Health"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0270","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/gme.0b013e31823cc5f7","article-title":"Effect of aerobic training on menopausal symptoms\u2014a randomized controlled trial","volume":"19","author":"Moilanen","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0275","doi-asserted-by":"crossref","first-page":"805","DOI":"10.7326\/0003-4819-137-10-200211190-00009","article-title":"Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials","volume":"137","author":"Kronenberg","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0280","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1001\/jama.2016.8012","article-title":"Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis","volume":"315","author":"Franco","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0285","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001395.pub4","article-title":"Phytoestrogens for menopausal vasomotor symptoms","volume":"10","author":"Lethaby","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0290","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007244.pub2","article-title":"Black cohosh (Cimicifuga spp.) for menopausal symptoms","volume":"12","author":"Leach","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.ygyno.2017.06.013_bb0295","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/13697130701864056","article-title":"Black cohosh: a cause of abnormal postmenopausal liver function tests","volume":"11","author":"Joy","year":"2008","journal-title":"Climacteric"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0300","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ygyno.2011.07.035","article-title":"Survivors of endometrial cancer: who is at risk for sexual dysfunction?","volume":"123","author":"Onujiogu","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0305","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2008.20.2424","article-title":"Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial","volume":"21","author":"Nout","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0310","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/gyno.1999.5526","article-title":"Patterns of failure in endometrial carcinoma stage IB grade 3 and IC patients treated with postoperative vaginal vault brachytherapy","volume":"75","author":"Chadha","year":"1999","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0315","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0167-8140(00)00171-7","article-title":"Post-operative high dose rate brachytherapy in patients with low to intermediate risk endometrial cancer","volume":"56","author":"Pearcey","year":"2000","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0320","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.fertnstert.2013.08.018","article-title":"Sexual dysfunction in women with cancer","volume":"100","author":"Falk","year":"2013","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0325","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0378-5122(95)00955-8","article-title":"Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women","volume":"23","author":"Bygdeman","year":"1996","journal-title":"Maturitas"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0330","first-page":"722","article-title":"Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee","volume":"92","author":"Cardozo","year":"1998","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0335","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001500.pub2","article-title":"Local oestrogen for vaginal atrophy in postmenopausal women","volume":"18","author":"Suckling","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0340","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/cmt.6.1.45.52","article-title":"A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer","volume":"6","author":"Dew","year":"2003","journal-title":"Climacteric"},{"key":"10.1016\/j.ygyno.2017.06.013_bb0345","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jsbmb.2016.03.016","article-title":"Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks","volume":"159","author":"Martel","year":"2016","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.ygyno.2017.06.013_bb0350","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/gme.0b013e3181c1ac01","article-title":"Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study","volume":"17","author":"Bachmann","year":"2010","journal-title":"Menopause"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581730954X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581730954X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T16:13:31Z","timestamp":1659111211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581730954X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S009082581730954X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.06.013","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of menopausal symptoms in women with gynecologic cancers","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}